PharmaEssentia: Company’s Board of Directors Approved Non-Binding Terms Sheet for the Distribution and Licensing of Ropeginterferon alfa-2b in the Latin America Region

Provided by: PharmaEssentia Corp.

SEQ_NO

1

announcement date

2022/05/29

Announcement time

12:59:35

Matter

 The Company's Board of Directors Approved the Non-
Binding Term Sheet for the Distribution and Licensing of
Ropeginterferon alfa-2b in the Latin American Region

Date of events

2022/05/27

What item it responds to

paragraph 10

Statement

1.Date of occurrence of the event:2022/05/27
2.Counterparty to the contract or commitment:
An international pharmaceutical company.
3.Relationship with the Company:None.
4.Starting and ending dates (or rescission date) of the
contract or commitment:NA
5.Major content (not applicable where rescinded):
The Company's Board of Directors approved the Non-Binding Term Sheet for
the distribution and licensing of Ropeginterferon alfa-2b in the Latin
American region, and authorized the Chairperson to negotiate and to sign
the definitive agreement.
6.Restrictive covenants (not applicable where rescinded):
As indicated in the confidentiality agreement.
7.Commitment (not applicable where rescinded):
As indicated in the confidentiality agreement.
8.Any other important agreement (not applicable where rescinded):
As indicated in the confidentiality agreement.
9.Effect on company finances and business:
Further announcement will be made upon the signing of the definitive
agreement.
10.Concrete purpose/objective:
To expand Ropeginterferon alfa-2b's market in the Latin American region
through registration, marketing, sales, and distribution.
11.Any other matters that need to be specified:
It takes a considerable time and expenses to develop a new drug.
In addition, the success of such development cannot be guaranteed.
Therefore, the investors will bear investment risk and should carefully
consider investment decisions.